NetFlix Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? NetFlix Inc trades at $71.3 (market cap $293.85B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: NetFlix Inc is far larger — about 57.8× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 126 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| NFLX | ORKA | |
|---|---|---|
Market Cap | $293.85B | $5.08B |
Volume | 39,920,482 | 685,276 |
Sector | Media | Health |
52-Week High | $124.13 | $113.08 |
52-Week Low | $67.06 | $26.19 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $299.03B | $4.21B |
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $70.48, down 0.18% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals with Q2 2026 EPS of $0.80 beating expectations, revenue of $45.18B in 2025, and a net income margin of 28.22%. Recent news highlights strategic moves into live sports and content expansion, while analyst consensus remains bullish with a $89.39 price target.
The outlook for NFLX is positive due to robust earnings growth and expanding profitability, but risks include competitive pressures and market volatility. The stock offers potential upside based on analyst targets, supported by strong cash flow and institutional interest, though investors should monitor execution on live content initiatives.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →